抗精神病薬市場レポート：2031年までの動向、予測、競合分析

世界の抗精神病薬市場の将来は、統合失調症、認知症、双極性障害、うつ病の各市場における機会により有望視されています。世界の抗精神病薬市場は2031年までに推定220億米ドルに達し、2025年から2031年までのCAGRは5.8%と予想されています。この市場の主な促進要因は、精神障害の有病率の上昇とメンタルヘルスに関する意識の高まりです。

• Lucintelの予測では、治療クラス別では、予測期間中、第2世代が引き続き大きなセグメントとなります。
• 用途別では、統合失調症の罹患率の増加により、統合失調症が引き続き最大セグメントとなります。
• 地域別では、メンタルヘルスケアサービスの導入増加や高齢化人口の急増により、北米が予測期間中最大の地域であり続けると思われます。

抗精神病薬市場の戦略的成長機会

抗精神病薬市場には、さまざまな用途で数多くの成長機会が存在します。これらの機会を活用することで、利害関係者はサービス提供を強化し、精神疾患の効果的な治療に対するニーズの高まりに対応することができます。

• 新規抗精神病薬へのニーズの高まり新しい抗精神病治療薬に対する需要は、精神疾患の有病率の上昇に牽引されています。この新興市場開拓のニーズに応えるため、革新的な研究開発への需要が高まっています。
• 小児精神医学への注目：抗精神病薬治療の小児への拡大には大きな可能性があります。年齢に応じた剤形や治療法を開発することで、さまざまな精神障害を経験する可能性のあるこの若年層のニーズに応えることができます。
• 精神科遠隔治療サービス：遠隔精神医療サービスの拡大は、メンタルヘルスケアにおけるギャップを埋めるのに役立っています。このようなサービスは、特に支援が届きにくい人々の患者参加を増やし、ライブビデオ回線を通じて精神科医とフォローアップセッションを行うことで、治療のアドヒアランスを促進します。
• 統合ケアモデル：薬物治療と他の一般的な患者ケアの方法を組み合わせた統合ケアモデル、特に慢性期ケアモデルを支援する傾向が高まっています。このアプローチは、精神保健医療従事者とプライマリー・ヘルスケア・システムとの結びつきを強化し、患者により良い、よりホリスティックなケアを提供します。
• 新興市場への世界展開：新興市場への進出は抗精神病薬業界にとって大きな成長機会となります。現地のニーズに合わせて製品やマーケティング戦略を調整することで、治療へのアクセスを改善し、様々な治療法の市場を拡大することができます。

このような成長戦略は抗精神病薬市場を押し上げ、患者の予後を改善し、必要不可欠なメンタルヘルスサービスの利用可能性を高めると思われます。

抗精神病薬市場の促進要因・課題

抗精神病薬市場には、技術改善、経済問題、規制面など、様々な促進要因・課題が影響を与えています。利害関係者がこのような複雑な職業で成功したいのであれば、これらの要因を理解することが重要です。

抗精神病薬市場を牽引する要因は以下の通り：

• 精神障害に対する意識の高まり：精神障害者の汚名に対する慰めであるにもかかわらず、精神病の治療薬は需要があり、抗精神病薬による治療希望者も急増しています。スタッフやマスメディアの関与により、人々は医療を求めるようになり、より多くの検査や迅速な診断につながっています。
• 医薬品開発プロセスにおける新たな動向：長時間作用型注射剤のようなドラッグデリバリーや製剤への新しいアプローチは、治療へのアドヒアランスを向上させ、その結果、薬剤の使用量が増加しています。
• ヘルスケアインフラの開発：いくつかの地域でヘルスケア構造が改善され、より良いメンタルヘルスサービスが提供されるようになったため、抗精神病薬が使用されるようになりました。
• 規制の進展：医薬品認可プロセスの簡素化に関する規制の進化は、抗精神病薬の新薬開発を促進し、業界内の競争を激化させています。
• 精神疾患の増加：世界の多くの人々の間で精神障害の症例が増加しているため、精神病性障害の強力な治療薬の開発が必要となっており、この市場の成長を高めています。

抗精神病薬市場における課題は以下の通り：

• 精神衛生問題に対する認識：認知度の向上にもかかわらず、精神病に対するスティグマが依然として市場成長の大きな障壁となっています。
• 新しい治療アプローチのコスト：統合失調症の新薬開発・普及にかかる高いコストは、中小企業にとって障壁となり、市場競争とイノベーションの妨げとなります。
• 規制の壁：新薬やバイオシミラーの上市までのプロセスは、複雑で時間のかかる規制要件のために遅れることがあり、メーカーや市場参入企業に不確実性をもたらしています。

治療成績を向上させ、患者により良い抗精神病薬を提供するためには、これらの課題に対処することが不可欠です。スティグマ、高コスト、規制状況、市場の飽和といった障害を克服することは、治療効果を高め、メンタルヘルスケア全体の状況を改善することにつながります。

目次

第1章 エグゼクティブサマリー

第2章 世界の抗精神病薬市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2019年から2031年までの市場動向と予測分析

• マクロ経済動向（2019～2024年）と予測（2025～2031年）
• 世界の抗精神病薬市場の動向（2019～2024年）と予測（2025～2031年）
• 治療クラス別：世界の抗精神病薬市場
  • 第一世代
  • 第二世代
• 流通チャネル別：世界の抗精神病薬市場
  • 病院薬局
  • 小売薬局
  • オンライン薬局
• 用途別：世界の抗精神病薬市場
  • 統合失調症
  • 痴呆
  • 双極性障害
  • うつ
  • その他

第4章 2019年から2031年までの地域別市場動向と予測分析

• 地域別：世界の抗精神病薬市場
• 北米の抗精神病薬市場
• 欧州の抗精神病薬市場
• アジア太平洋地域の抗精神病薬市場
• その他地域の抗精神病薬市場

第5章 競合分析

• 製品ポートフォリオ分析
• 業務統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • 治療クラス別：世界の抗精神病薬市場の成長機会
  • 流通チャネル別：世界の抗精神病薬市場の成長機会
  • 用途別：世界の抗精神病薬市場の成長機会
  • 地域別：世界の抗精神病薬市場の成長機会
• 世界の抗精神病薬市場の新たな動向
• 戦略分析
  • 新製品開発
  • 世界の抗精神病薬市場の能力拡大
  • 世界の抗精神病薬市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 主要企業の企業プロファイル

• Alkermes
• Eli Lilly and Company
• Bristol-Myers Squibb
• Otsuka Holdings
• AbbVie
• Johnson & Johnson
• Teva Pharmaceutical Industries
• Pfizer
• Astrazeneca
• Dr. Reddy's Laboratories

The future of the global antipsychotic drug market looks promising with opportunities in the schizophrenia, dementia, bipolar disorder, and depression markets. The global antipsychotic drug market is expected to reach an estimated $22 billion by 2031 with a CAGR of 5.8% from 2025 to 2031. The major drivers for this market are the rise in the prevalence of mental disorders and growing awareness regarding mental health.

• Lucintel forecasts that, within the therapeutic class category, second-generation will remain the larger segment over the forecast period.
• Within the application category, schizophrenia will remain the largest segment due to an increase in incidences of schizophrenic disorders.
• In terms of regions, North America will remain the largest region over the forecast period due to a rise in adoption of mental healthcare services and a surge in the aging population.

Gain Valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Antipsychotic Drug Market

The antipsychotic drug market has undergone a structural change induced by various emerging trends. These trends highlight changes in treatment habits, growing technologies, and the disease burden of patients, with the ultimate goal of making therapies more effective and improving patients' quality of life.

• Personalized Medicine: More pharmacogenomic testing to prevent relapse is being utilized when treating antipsychotics, as the era of personalized medicine has arrived. This approach aims to maximize potency and minimize observable adverse effects, ensuring better compliance and outcomes.
• Digital Health Integration: With advancements in telehealth systems and mobile applications, it has become easier to manage antipsychotic therapy. These tools allow for more active surveillance of treatment, support compliance, and provide better access to healthcare professionals for improved management.
• Long-Acting Injectable Formulations: Chronic patients with schizophrenia show better compliance with initiation and maintenance treatment due to the introduction and increased use of long-acting injectable antipsychotics (LAIs). LAIs reduce the burden of daily pill intake, which can lead to the violence associated with non-compliance, making the overall treatment more effective.
• Focus on Co-Occurring Conditions: Patients with psychotic disorders often have other comorbid conditions such as anxiety and depression. There is a growing realization that these must be addressed. The trend toward concurrent treatment of such disorders is becoming more common, contributing to overall patient care.
• Regulatory Evolution: The changing regulatory environment is flattening drug development timelines, leading to more drugs entering the antipsychotic market. This results in new drugs becoming available more rapidly, which increases competition and ultimately improves treatment options for patients.

These trends are redefining the antipsychotic drug market by providing more individualized and holistic treatment. If these trends persist, they will likely improve treatment outcomes and enhance patient satisfaction, especially for those with a complex variety of mental health disorders.

Recent Developments in the Antipsychotic Drug Market

Important developments have defined the antipsychotic drug market, enhancing treatment and patient care. Several other developments are changing the course of history, including technological advancements, regulatory changes, and evolving attitudes toward mental health.

• New Drug Approvals: There has been an increasing approval of new antipsychotic medications, along with favorable changes in their safety profiles, opening new avenues for patient treatment. New drugs are developed to treat specific symptoms and benefit patients who do not respond well to standard therapies.
• Emergence of Generic Formulations: The availability of generic antipsychotic pharmaceuticals is making it easier and more affordable for patients to receive treatment. This is especially important in low-income countries where the cost of essential drugs can be a major barrier to access.
• Advancements in Delivery Methods: The introduction of new drug administration techniques, such as long-acting injectables, is helping patients with chronic mental illness comply with treatment. These products help reduce the need for daily medication intake, minimizing relapse cases.
• Governments Working to Improve Access and Financing of Mental Health Services: Many governments are implementing policies to improve access to mental health care and resources. Such initiatives promote clearer diagnoses and approaches toward mental health disorders.
• Disease Management: There is an increase in the use of collaborative care models, where mental health care is provided alongside primary care. This integrated approach allows for both physical and mental health needs to be addressed in a single visit.

These developments are pushing the antipsychotic drug market forward, improving patient outcomes, and expanding the availability of mental health services.

Strategic Growth Opportunities for Antipsychotic Drug Market

The antipsychotic drug market presents numerous opportunities for growth across various applications. By taking advantage of these opportunities, stakeholders can enhance service provision and respond to the increasing need for effective treatments for mental health disorders.

• Increasing Need for New Antipsychotic Drugs: The demand for new antipsychotic therapeutics is driven by the rising prevalence of mental illnesses. There is a growing demand for innovative research and drug development to meet the needs of this expanding market.
• Focus on Pediatric Psychiatry: There is significant potential in expanding antipsychotic treatment to pediatric populations. Developing age-appropriate dosage forms and treatment methods will cater to the needs of this young group, who may experience a range of mental health disorders.
• Telepsychiatry Services: The expansion of telepsychiatry services is helping bridge gaps in mental health care. These services increase patient participation, particularly among hard-to-reach populations, and facilitate adherence to treatment through follow-up sessions with psychiatrists via live video link.
• Integrated Care Models: There is a growing trend toward integrated care models that combine drug treatment with other common methods of patient care, particularly in support of the chronic care model. This approach strengthens the connection between mental health workers and the primary healthcare system, providing better and more holistic care to patients.
• Global Expansion into Emerging Markets: Expanding into emerging markets presents a significant growth opportunity for the antipsychotic drug industry. Tailoring products and marketing strategies to local needs can improve access to treatment and expand the market for various therapies.

These growth strategies will push the antipsychotic drug market forward, improving patient outcomes and increasing the availability of essential mental health services.

Antipsychotic Drug Market Driver and Challenges

Various drivers and challenges impact the antipsychotic Drug market such as technological improvements, economic issues, and regulatory aspects. It is important to understand these factors if stakeholders want to succeed in such a complicated occupation.

The factors responsible for driving the antipsychotic drug market include:

• Increasing Consciousness of Mental Disorders: Despite being a consolation to the stigma attributed to mentally challenged persons, medicines for psychosis are in demand, and antipsychotic treatment seeking is also burgeoning. Staff and mass media involvement is making people seek health care more which leads to more testing and faster diagnosis.
• Emerging Trends In The Drug Development Process: New approaches to drug delivery and formulation such as long-acting injectables are resulting in better adherence to treatment and therefore growth in the use of the drug.
• Development Of Healthcare Infrastructure: There have been upgrades in the healthcare structure in several places enabling better mental health services hence the use of antipsychotic drugs.
• Regulatory Favor: Regulatory evolution concerning simplification of the drug licensing process has led to positive enhancement of the development of new antipsychotic drugs increasing competition within the industry.
• Rising Incidence Of Mental Health Disorders: The increased cases of mental disorders among many people in the world are making it necessity to develop potent medications for psychotic disorders which enhance the growth of this market.

Challenges in the antipsychotic drug market are:

• Perception of Mental Health Problems: Despite increased awareness, mental illness stigma remains a significant barrier to growth in the market.
• Cost of New Treatment Approaches: The high cost of developing and promoting new drugs for schizophrenia can be a barrier for smaller companies, hindering competition and innovation in the market.
• Regulatory Barriers: The process of bringing new drugs and biosimilars to market can be delayed due to complex and time-consuming regulatory requirements, creating uncertainty for manufacturers and market participants.

Addressing these challenges is essential for improving treatment outcomes and ensuring the availability of better antipsychotic drugs for patients. Overcoming obstacles such as stigma, high costs, regulatory hurdles, and market saturation will increase the effectiveness of treatments and enhance the overall mental health care landscape.

List of Antipsychotic Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies antipsychotic drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the antipsychotic drug companies profiled in this report include-

• Alkermes
• Eli Lilly and Company
• Bristol-Myers Squibb
• Otsuka Holdings
• AbbVie
• Johnson & Johnson
• Teva Pharmaceutical Industries
• Pfizer
• Astrazeneca
• Dr. Reddy's Laboratories

Antipsychotic Drug by Segment

The study includes a forecast for the global antipsychotic drug market by therapeutic class, distribution channel, application, and region.

Antipsychotic Drug Market by Therapeutic Class [Analysis by Value from 2019 to 2031]:

• First-generation
• Second-generation

Antipsychotic Drug Market by Distribution Channel [Analysis by Value from 2019 to 2031]:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Antipsychotic Drug Market by Application [Analysis by Value from 2019 to 2031]:

• Schizophrenia
• Dementia
• Bipolar Disorder
• Depression
• Others

Antipsychotic Drug Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Antipsychotic Drug Market

The antipsychotic drug market has seen favorable changes due to rising global awareness of mental health, advancements in drug development technologies, and a changing regulatory environment. Countries like the United States, China, Germany, India, and Japan are experiencing steady developments, including drug approvals, new treatment options, and expanded mental health services. These trends reflect a growing understanding of the importance of mental health and appropriate treatment.

• United States: In the U.S., the antipsychotic drug market has seen multiple new drug approvals, including long-acting injectable drugs that improve patient compliance. The new generation of medicines is being developed alongside functional genomics tools that help tailor antipsychotic medications to specific patients. Telepsychiatry has also gained widespread acceptance, improving access to mental health care, especially during the COVID-19 pandemic. These trends are enhancing patient outcomes by addressing primary mental health conditions and comorbid factors.
• China: The antipsychotic drug market in China has experienced rapid growth due to increased recognition of mental health issues and government emphasis on mental health programs. The market has been further supported by the emergence of generic versions of popular antipsychotic drugs, making treatment more affordable. Reforms in mental health policy and staff training are improving diagnosis and care. Additionally, technologies like digital health are assisting in patient monitoring and follow-up care.
• Germany: The antipsychotic drug market in Germany has progressed positively with the development of novel drugs and improvements in the regulatory process. These new drugs, which have better side effect profiles, are attracting interest in the market. Germany's healthcare system emphasizes evidence-based treatment protocols and psychosocial rehabilitation while increasing budget allocations and community awareness initiatives are improving societal response to antipsychotic treatments.
• India: The antipsychotic drug market in India is poised for significant growth due to the high prevalence of mental disorders and the decreasing stigma associated with mental health issues. Efforts to develop mental health care through policy initiatives and partnerships with NGOs are supporting market growth. The introduction of low-cost generics is also increasing access to antipsychotic medications. Awareness programs aimed at stigma reduction and early treatment are improving patient compliance.
• Japan: The antipsychotic market in Japan is characterized by innovation, particularly in products targeting symptoms of schizophrenia and bipolar disorder. Recent amendments to drug approval laws have expedited the availability of new treatments, improving the landscape for mental health care. The use of bipolar disorder medications, combined with cognitive behavioral therapy (CBT) and support groups, is on the rise. Furthermore, the use of telemedicine and mobile apps is helping enhance patient adherence and improve treatment efficacy.

Features of the Global Antipsychotic Drug Market

Market Size Estimates: Antipsychotic drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecasts (2025 to 2031) by various segments and regions.

Segmentation Analysis: Antipsychotic drug market size by therapeutic class, distribution channel, application, and region in terms of value ($B).

Regional Analysis: Antipsychotic drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different therapeutic class, distribution channels, applications, and regions for the antipsychotic drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the antipsychotic drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the antipsychotic drug market by therapeutic class (first-generation and second-generation), distribution channel (hospital pharmacy, retail pharmacy, and online pharmacy), application (schizophrenia, dementia, bipolar disorder, depression, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Antipsychotic Drug Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Antipsychotic Drug Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Antipsychotic Drug Market by Therapeutic Class
  • 3.3.1: First-generation
  • 3.3.2: Second-generation
• 3.4: Global Antipsychotic Drug Market by Distribution Channel
  • 3.4.1: Hospital Pharmacy
  • 3.4.2: Retail Pharmacy
  • 3.4.3: Online Pharmacy
• 3.5: Global Antipsychotic Drug Market by Application
  • 3.5.1: Schizophrenia
  • 3.5.2: Dementia
  • 3.5.3: Bipolar Disorder
  • 3.5.4: Depression
  • 3.5.5: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Antipsychotic Drug Market by Region
• 4.2: North American Antipsychotic Drug Market
  • 4.2.1: North American Market by Therapeutic Class: First-generation and Second-generation
  • 4.2.2: North American Market by Application: Schizophrenia, Dementia, Bipolar Disorder, Depression, and Others
• 4.3: European Antipsychotic Drug Market
  • 4.3.1: European Market by Therapeutic Class: First-generation and Second-generation
  • 4.3.2: European Market by Application: Schizophrenia, Dementia, Bipolar Disorder, Depression, and Others
• 4.4: APAC Antipsychotic Drug Market
  • 4.4.1: APAC Market by Therapeutic Class: First-generation and Second-generation
  • 4.4.2: APAC Market by Application: Schizophrenia, Dementia, Bipolar Disorder, Depression, and Others
• 4.5: ROW Antipsychotic Drug Market
  • 4.5.1: ROW Market by Therapeutic Class: First-generation and Second-generation
  • 4.5.2: ROW Market by Application: Schizophrenia, Dementia, Bipolar Disorder, Depression, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Antipsychotic Drug Market by Therapeutic Class
  • 6.1.2: Growth Opportunities for the Global Antipsychotic Drug Market by Distribution Channel
  • 6.1.3: Growth Opportunities for the Global Antipsychotic Drug Market by Application
  • 6.1.4: Growth Opportunities for the Global Antipsychotic Drug Market by Region
• 6.2: Emerging Trends in the Global Antipsychotic Drug Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Antipsychotic Drug Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Antipsychotic Drug Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Alkermes
• 7.2: Eli Lilly and Company
• 7.3: Bristol-Myers Squibb
• 7.4: Otsuka Holdings
• 7.5: AbbVie
• 7.6: Johnson & Johnson
• 7.7: Teva Pharmaceutical Industries
• 7.8: Pfizer
• 7.9: Astrazeneca
• 7.10: Dr. Reddy's Laboratories